<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66444">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02240888</url>
  </required_header>
  <id_info>
    <org_study_id>2011/341</org_study_id>
    <secondary_id>Vaccimil</secondary_id>
    <nct_id>NCT02240888</nct_id>
  </id_info>
  <brief_title>Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections</brief_title>
  <acronym>Vaccimil</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this project is to study the influence of modern anti-inflammatory
      treatments in established inflammatory rheumatic diseases (IRD) on immune response elicited
      by pneumococcal vaccination using 13-valent conjugate vaccine and influenza vaccination. In
      addition, the aim is to study the clinical aspects of vaccination regarding: tolerability in
      immunosuppressed patients with IRD, impact on existing rheumatic disease, possible
      association with onset of new autoimmune diseases, long-term immunity following pneumococcal
      vaccination, efficacy in preventing invasive pneumococcal diseases and influenza related
      serious infections. Results from this study are expected to bridge the existing knowledge
      gap and contribute to body of evidence needed for recommendations and implementation of
      vaccination program in IRD patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>antibody response following vaccination</measure>
    <time_frame>4-6 weeks after pneumococcal and influenza vaccination</time_frame>
    <description>measurement of antibody levels against different pneumococcal capsular serotypes and 3 influenza virus strains</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>within 2 weeks after each vaccination</time_frame>
    <description>Number of Participants with Serious and Non-Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long-term immunity following pneumococcal vaccination</measure>
    <time_frame>1 year after pneumococcal vaccination using conjugate vaccine</time_frame>
    <description>measurement of antibody levels against different pneumococcal polysaccharide serotypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long-term immunity following pneumococcal vaccination</measure>
    <time_frame>3 years after pneumococcal vaccination</time_frame>
    <description>measurement of antibody levels against different pneumococcal capsular serotypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long-term immunity after vaccination with pneumococcal conjugate vaccine</measure>
    <time_frame>5 years after vaccination</time_frame>
    <description>measurement of antibody levels against different pneumococcal polysaccharide serotypes</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The occurence of severe pneumococcal infections in immunized patients</measure>
    <time_frame>within 5 years after pneumococcal vaccination</time_frame>
    <description>Analysis of the occurence of severe pneumococcal infections in immunized patients compared to matched not-immunized controls</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>RA</condition>
  <condition>SLE</condition>
  <condition>Vasculitis</condition>
  <condition>Scleroderma</condition>
  <condition>Sjögrens</condition>
  <condition>Syndrome</condition>
  <arm_group>
    <arm_group_label>vaccinated patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with different inflammatory rheumatic disease immunized with 0,5 mg pneumococcal conjugate vaccine i.m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccinated controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy controls immunized with 0,5 mg pneumococcal conjugate vaccine i.m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>seasonal influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with different inflammatory rheumatic diseases immunized with 0,5 mg seasonal influenza vaccine i.m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-vaccinated controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy controls immunized with 0,5 mg seasonal influenza vaccine i.m.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0,5 mg Prevenar i.m.</intervention_name>
    <arm_group_label>vaccinated patients</arm_group_label>
    <arm_group_label>vaccinated controls</arm_group_label>
    <arm_group_label>seasonal influenza vaccine</arm_group_label>
    <arm_group_label>non-vaccinated controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0,5 mg seasonal influenza vaccine i.m.</intervention_name>
    <arm_group_label>vaccinated patients</arm_group_label>
    <arm_group_label>vaccinated controls</arm_group_label>
    <arm_group_label>seasonal influenza vaccine</arm_group_label>
    <arm_group_label>non-vaccinated controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with IRD receiving active anti-rheumatic treatments with DMARDs or
             biological remedies are offered to participate in the study. The protocol permits
             stratification for prednisolone usage, smoking habits and alcohol consumption.

        Exclusion Criteria:

          -  age &lt;18 years;

          -  pregnancy,

          -  known intolerance of vaccine,

          -  ongoing infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meliha C Kapetanovic, MD, PhD, assocciated prof.</last_name>
    <phone>004646171625</phone>
    <email>meliha.c_kapetanovic@med.lu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skåne University hospital, Dept of rheumatology</name>
      <address>
        <city>Lund</city>
        <zip>SE-22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meliha C Kapetanovic, MD, PhD, assoc. prof</last_name>
      <phone>++4646171625</phone>
      <email>meliha.c_kapetanovic@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Meliha C Kapetanovic, MD, PhD, assoc prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 15, 2014</lastchanged_date>
  <firstreceived_date>September 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Region Skane</investigator_affiliation>
    <investigator_full_name>meliha crnkic kapetanovic</investigator_full_name>
    <investigator_title>MD, PhD, associate professor</investigator_title>
  </responsible_party>
  <keyword>pneumococcal</keyword>
  <keyword>vaccination</keyword>
  <keyword>antibody</keyword>
  <keyword>response</keyword>
  <keyword>immunosuppressive</keyword>
  <keyword>treatment</keyword>
  <keyword>inflammatory</keyword>
  <keyword>rheumatic</keyword>
  <keyword>disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
